Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.320
-0.080 (-5.71%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Outlook Therapeutics Stock Forecast
OTLK's stock price has decreased by -85.91% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Outlook Therapeutics stock have an average target of 10.2, with a low estimate of 3.00 and a high estimate of 24. The average target predicts an increase of 672.73% from the current stock price of 1.32.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 24, 2025.
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 4 | 4 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $33 → $24 | Strong Buy | Maintains | $33 → $24 | +1,718.18% | Feb 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $3 | Strong Buy | Maintains | $30 → $3 | +127.27% | Feb 18, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +127.27% | Feb 18, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +809.09% | Jan 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +2,172.73% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
10.34M
Revenue Next Year
40.18M
from 10.34M
Increased by 288.46%
EPS This Year
-2.02
from -4.06
EPS Next Year
-1.08
from -2.02
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.8M | 53.5M | 136.5M | ||
| Avg | 10.3M | 40.2M | 116.9M | ||
| Low | 4.9M | 24.5M | 95.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 417.3% | 239.8% | ||
| Avg | - | 288.5% | 191.0% | ||
| Low | - | 136.9% | 138.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.76 | -1.00 | 1.32 | ||
| Avg | -2.02 | -1.08 | 0.95 | ||
| Low | -3.19 | -1.14 | 0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.